Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash & Equivalents: 2014-2025

Historic Cash & Equivalents for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to $34.2 million.

  • CytomX Therapeutics' Cash & Equivalents fell 15.75% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 15.75%. This contributed to the annual value of $38.1 million for FY2024, which is 121.61% up from last year.
  • Per CytomX Therapeutics' latest filing, its Cash & Equivalents stood at $34.2 million for Q3 2025, which was down 30.29% from $49.0 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Cash & Equivalents peaked at $329.7 million during Q1 2021, and registered a low of $17.2 million during Q4 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $40.6 million (2024), whereas its average is $40.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 130.08% in 2021, then crashed by 91.13% in 2023.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' Cash & Equivalents stood at $205.5 million in 2021, then decreased by 5.78% to $193.7 million in 2022, then plummeted by 91.13% to $17.2 million in 2023, then spiked by 121.61% to $38.1 million in 2024, then dropped by 15.75% to $34.2 million in 2025.
  • Its last three reported values are $34.2 million in Q3 2025, $49.0 million for Q2 2025, and $47.6 million during Q1 2025.